{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-25-000121","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2025-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.709736+00:00","generated_at":"2026-05-16T13:47:37.253279+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nurix releases Phase 1 CLL/SLL data: 83% ORR, 22.1mo PFS; WM ORR 75.0% at ASH 2025","bullets":["Phase 1a CLL/SLL ORR 83.0% (47 evaluable), including 4.3% complete responses; median PFS 22.1 months, DOR 20.1 months.","Phase 1b randomized comparison: 600mg RP2D showed 83.3% ORR vs 73.7% for 200mg; PFS trend favoring 600mg.","WM (n=28 evaluable) ORR 75.0% including 10.7% VGPR; median follow-up 8.1 months, median DOR and PFS not reached.","Safety: well tolerated across doses; no dose-limiting toxicities, systemic fungal infections, or Grade 4 infections.","Pivotal Phase 2 DAYBreak-CLL-201 enrolling globally; 600mg RP2D selected for further development."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-25-000121","json":"https://secwatch.observer/filing/0001549595-25-000121.json","markdown":"https://secwatch.observer/filing/0001549595-25-000121.md","text":"https://secwatch.observer/filing/0001549595-25-000121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000121/0001549595-25-000121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000121/nrix-20251206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:47:37.253279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}